FindTrial
Sign In

A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects with HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-523793-16-00
Enrollment
8
Registered
2026-04-20
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Homeostatic iron regulator gene-related hereditary hemochromatosis

Brief summary

Change from baseline in magnetic resonance imaging (MRI)-based liver iron concentration (LIC) ,

Interventions

DRUGCSL624
DRUGCapsule (placebo matching vamifeport)

Sponsors

CSL Behring LLC
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Change from baseline in magnetic resonance imaging (MRI)-based liver iron concentration (LIC) ,—

Outcome results

None listed

Source: EU CTIS · Data processed: Apr 22, 2026